U.S., April 8 -- ClinicalTrials.gov registry received information related to the study (NCT07516015) titled 'Clinical Effectiveness and Safety of SHR-A1811 in Chinese Patients With HER2-Altered NSCLC' on March 31.
Brief Summary: SHR-A1811 is an approved therapy for non-small cell lung cancer (NSCLC) in China. Despite the clinical trial evidence, there is no real-world data of SHR-A1811 used in Chinese lung cancer patients with HER2 alteration.
This real world, prospective study will assess the effectiveness and safety of SHR-A1811 in patients with locally advanced or metastatic, HER2-Altered NSCLC in real-world setting.
Study Start Date: April 10
Study Type: OBSERVATIONAL
Condition:
NSCLC
Intervention:
OTHER: No Drug
This is an non...